CRTX.L

CRISM Therapeutics Corporation
CRISM Therapeutics - Delivery Method Validated in Peer Reviewed Journal
3rd September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5932C
CRISM Therapeutics Corporation
03 September 2024
 

 

3 September 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Drug Delivery Method Validated in Peer Reviewed Journal

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to confirm that a recent peer reviewed research article, Local Delivery  of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration, demonstrated that the local delivery of the chemotherapy drug irinotecan directly into the border of the resection margin after a tumour has been removed offers a safe route of administration for glioblastoma patients with none of the normal side effects associated with traditional chemotherapy delivered  by injection or orally.

The research article, in the journal Cancers, can be viewed at: https://www.mdpi.com/2072-6694/16/17/3008

The research article is co-authored by academics at the University of Birmingham and the Royal Bristol Hospital for Children, led by Christopher McConville, Associate Professor or Pharmaceutics at the University of Birmingham and also Chief Scientific Officer at CRISM Therapeutics.  Cancers is a peer reviewed, open access, medical journal published by MDPI covering all fields of oncology. 

The safety of the local administration of irinotecan to the resection margin confirmed by this research article validates CRISM's decision to use irinotecan in ChemoSeed as a treatment for high grade gliomas and is expected to support its clinical trial application.  Furthermore, the article concludes that sustaining the delivery of irinotecan at the resection margin using an implantable device, such as ChemoSeed, could improve survival rates in glioblastoma patients.

Commenting on the article in the peer reviewed journal, CRISM CEO Andrew Webb said: "The publication of this paper validates CRISM's drug delivery approach to administer irinotecan locally into the resection margin and we are pleased that this method of drug delivery is receiving greater recognition within the oncology community.  In addition, this validation will support our clinical trial application which remains on track for H2 this year."

 

-Ends-

 

 

Enquiries:

 

Company

Nomad and Broker

Financial PR

CRISM Therapeutics Corporation

S.P. Angel Corporate Finance LLP

Burson Buchanan

Andrew Webb, CEO

Chris McConville, CSO

Richard Morrison

Adam Cowl

Mark Court / Jamie Hooper

CRISM@buchanancomms.co.uk

via Burson Buchanan

+44 (0) 20 3470 0470

+44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed® in high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.

For more information please visit: https://www.crismtherapeutics.com/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUCABUPCGAP]]>
TwitterFacebookLinkedIn